Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions

Lee, G.-Y.; Kim, S.-M.; Rim, So Yi; Choi, Ho Sun; Park, C.-S.; Nam, Jong Hee

doi:10.1111/j.1048-891x.2005.14417.x

Cited by 25 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Choi et al [26], HPV56 had a relatively low prevalence, but it was more commonly detected in low-grade cervical intraepithelial neoplasia (CIN) than were HPV16, HPV58, and HPV52. HPV52 has been often noted as one of the prevalent high-risk HPV types in precancerous lesions in the Korean population, followed by HPV16, HPV18, and HPV58 [27,28]. In comparison, the prevalence of HPV16 in our study was considerably low (1.8% of the women overall and 21.8% of the high-risk HPV-positive women), with only a 12.5% prevalence among the 22 subjects who had HSIL or worse.…”

Section: Discussionmentioning

confidence: 99%

Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women

Kim

2013

Obstet Gynecol Sci

View full text Add to dashboard Cite

ObjectiveWe investigated the type-specific high-risk human papillomavirus (HPV) prevalence and distribution according to cervical cytology and age in healthy Korean women.MethodsA retrospective cross-sectional study was conducted with 7,014 consecutive subjects undergoing both liquid-based cervical cytology and HPV genotyping test by DNA chip for cervical cancer screening. The type-specific prevalence and distribution of individual high-risk HPV types were assessed according to cervical cytology and age groups (<30, 30-39, 40-49, 50-59, and ≥60 years old).ResultsIn total, the most common HPV genotype was HPV58 (23.9% of all high-risk HPV-positive subjects), followed by HPV16 (21.8%), HPV52 (16.6%), and HPV18 (11.7%). Regarding cervical cytology and age groups, the proportion of HPV56 strongly increased with the increasing severity of cervical cytology (P for trend=0.041). An age-specific decline in the overall high-risk HPV prevalence was reaffirmed, and the proportion of HPV52 declined markedly with age (P for trend=0.014).ConclusionThe type-specific prevalence of high-risk HPV types significantly varies according to cervical cytology and age. It may imply that these types have different to develop into precancerous lesions in normal cervix.

show abstract

Section: Discussionmentioning

confidence: 99%

Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women

Kim

2013

Obstet Gynecol Sci

View full text Add to dashboard Cite

show abstract

“…Applying this assay, the denatured single strand DNA was hybridized with 2 RNA probe mixtures complementary to the 13 high-risk HPV genotype sequences (16,18,31,33,35,39,45,51,52,56,58,59 and 68) and 5 lowrisk genotypes (6, 11, 42, 43 and 44). It was performed by following the manufacturer's instructions using an automated HC2 system (Terry et al, 2001;Lee et al, 2005). The emitted light was measured as RLU/PC, the luminescence of the 1.0 pg/ml HPV 16 standard from the kit (Cañadas MP et al, 2012).…”

Section: Hybrid Capture 2 (Hc2)mentioning

confidence: 99%

Clinical Prediction Based on HPV DNA Testing by Hybrid Capture 2 (HC2) in Combination with Liquid-based Cytology (LBC)

Junyangdikul

Tanchotsrinon²,

Chansaenroj³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Primary screening by HPV DNA testing is an effective method for reducing cervical cancer and has proven more sensitive than cytology. To advance this approach, many molecular methods have been developed. Hybrid capture 2 provides semi-quantitative results in ratios of relative light units and positive cutoff values (RLU/ PC). Twenty-five thousand and five patients were included in this study to analyze the correlation between the ratio of RLU/PC and stage of cervical dysplasia. The results show that the RLU/PC ratios ranged from 0-3500 while almost normal cases, ASC-US and ASC-H, had values below 200. Of those samples negative for cytology markers, 94.6% were normal and their RLU/PC ratios were less than 4. With an RLU/PC ratio greater than 4 and less than or equal to 300, the percentages in all age groups were normal 53.6%, LSIL 20.2%, ASC-US 17.2%, HSIL 6.13%, ASC-H 2.72%, and AGC 0.11%, respectively. In contrast, 64.0% of samples with a RLU/ PC ratio greater than 300 and less than or equal to 3500 were LSIL. These results should contribute to cost effective cervical cancer management strategies. Further studies of associations with particular HPV genotypes would be useful to predict the risk of progression to cancer.

show abstract

“…The assays followed the manufacturer's protocol [15]. A DNA chip scanner (GenePix Pro 3.10; GenePix 4000B, Laser power-33%, PMT-880; Axon Instrument Inc., Union City, CA, USA) was used to visualize the hybridized HPV DNA.…”

Section: Methodsmentioning

confidence: 99%

Clinical Validation of AdvanSure GenoBlot Assay as Primary Screening and Test of Cure for Human Papillomavirus Infection

Kahng

Lee

et al. 2014

Ann Lab Med

View full text Add to dashboard Cite

BackgroundClinical specificity and sensitivity are essential factors in the adoption of a human papillomavirus (HPV) test as a primary screening tool and test of cure after treatment of cervical cancer and precancerous lesions (High-Risk-Lesion). Using histologically-confirmed High-Risk-Lesion-patient specimens with postoperative follow-ups, we performed clinical validation of the AdvanSure GenoBlot Assay (GenoBlot; LG Life Sciences, Korea).MethodsThe study population included 100 cases with High-Risk-Lesion, 96 with high-risk genotype positive and cervical intraepithelial neoplasia (CIN) 1 or better, and 39 with HR-negative and better than CIN 1. Forty-eight High-Risk-Lesion cases received follow-up HPV exams after surgery. For validation as a test of cure, 48 preoperative specimens (PreOP) and 78 postoperative specimens (PostOP) from 48 subjects were separately analyzed. The results of HPV DNA chip tests (HPVDNAChip; BioMedLab Co., Korea) and sequencing were cross-compared.ResultsThe concordance rates for each genotype between HPVDNAChip and GenoBlot were between 96.3-100%. The accuracy of HPVDNAChip and GenoBlot was 87.9% and 96.6%, respectively. Genotype-based specificity for High-Risk-Lesion detection was higher than 87% for both assays; genotype 16 showed the highest sensitivity. In the PostOP group, the positive rates for HPVDNAChip and GenoBlot were 30.8% and 47.4%, respectively.ConclusionsGenoBlot showed a higher positive rate than HPVDNAChip for each genotype, with concordance rate and accuracy being similar to previous reports. As a test of cure, GenoBlot performed better than the HPVDNAChip.

show abstract

Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions

Cited by 25 publications

References 27 publications

Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women

Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women

Clinical Prediction Based on HPV DNA Testing by Hybrid Capture 2 (HC2) in Combination with Liquid-based Cytology (LBC)

Clinical Validation of AdvanSure GenoBlot Assay as Primary Screening and Test of Cure for Human Papillomavirus Infection

Contact Info

Product

Resources

About